Molecular Partners (NASDAQ:MOLN) Price Target Lowered to $3.75 at JPMorgan Chase & Co.

Molecular Partners (NASDAQ:MOLN) had its target price dropped by stock analysts at JPMorgan Chase & Co. from $4.00 to $3.75 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential downside of 13.67% from the company’s current price.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Molecular Partners in a report on Monday, December 1st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.88.

Molecular Partners Price Performance

NASDAQ MOLN traded down $0.18 on Monday, reaching $4.34. The stock had a trading volume of 3,392 shares, compared to its average volume of 6,145. Molecular Partners has a 1-year low of $3.36 and a 1-year high of $5.95. The company has a market cap of $175.39 million, a P/E ratio of -2.26 and a beta of 1.08. The firm has a fifty day moving average of $3.96 and a two-hundred day moving average of $3.81.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.05. Research analysts predict that Molecular Partners will post -1.93 EPS for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.